A Phase 3 interventional study of Guselkumab and Placebo Injection in Psoriasis, sponsored by Janssen-Cilag International NV. Completed at 90 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-01-23.
Sponsored by Janssen-Cilag International NV (part of Johnson & Johnson) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 29 studies testing guselkumab in Psoriasis — 8 open to participants now, 9 under way, 1 of them phase 3. guselkumab · Psoriasis.
Among the 29 studies testing guselkumab in Psoriasis, this one is the 3rd largest by enrollment, is one of 2 that started in 2019, is one of 12 in phase 3, and was the 14th registered.
2,030 studies on the registry are indexed under Psoriasis; 276 are open to participants now.
Browse Psoriasis studies →8 of the 29 studies testing guselkumab in Psoriasis are open now, in 5 countries. Recruiting first, the newest first:
Janssen Research & Development, LLC · Sites in United States
Ages 18+ · Women only
University Hospital, Ghent · Sites in Belgium
Ages 18+
Second Affiliated Hospital, School of Medicine, Zhejiang University · Sites in China
Ages 18+
Fondazione Policlinico Universitario Campus Bio-Medico · Sites in Italy
Ages 18–80
University of California, San Francisco · Sites in United States
Ages 18+ · Healthy volunteers
By country, each count listing its studies:
guselkumab: first FDA approval 2017 (TREMFYA), first EMA approval 2017. What it is approved for, and how studies give it, is on its page →
Of the 173 Psoriasis studies recruiting now, 91 (53%) set no upper age limit and 66 (38%) stop at 75 or younger; 25 take children under 18; 40 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
29 studies; the count open now beside each. This study's row is marked.
First in 2011; this study’s year is marked. 2 started in 2019.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 880 is above the median of 75 across 1,567 interventional studies indexed under Psoriasis.
Median enrollment 120 across the 29 interventional studies. Of the 20 that completed or were terminated, 12 (60%) have results posted.
This tab as a report to print or save as PDF → With an account.
20 of 29 have an industry lead sponsor. The 10 most frequent:
This study is registered under Janssen-Cilag International NV, one of the names counted as Johnson & Johnson. Under that name alone:
Janssen-Cilag International NV is the lead sponsor of 67 studies on the registry; none are open to participants now.
76 studies in Psoriasis by Johnson & Johnson: 3 open now, 12 under way, 7 of them phase 3. Of 64 finished, 33 (52%) have results posted.
Among the 76 studies in Psoriasis by Johnson & Johnson, this one is the 5th largest by enrollment of the 58 interventional ones that give a count, is one of 3 that started in 2019, is one of 36 in phase 3, and was the 55th registered.
Johnson & Johnson’s Psoriasis studies by the year they started, since 2002.
3 of the studies testing guselkumab in Psoriasis that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05004727NYU Langone HealthMulti-Center PAMPA Study | 2026-12-31 |
| NCT07532486Second Affiliated Hospital, School of Medicine, Zhejiang UniversityA Study to Evaluate Comparative Efficacy and Safety of Guselkumab in High-dose and Extended-interval Versus Standard-dose in Chinese Participants of Moderate-to-severe Plaque Psoriasis | 2027-07-10 |
| NCT07654751Janssen Research & Development, LLCA Remotely Conducted Study to Assess Concentration of TREMFYA in Breast Milk of Lactating Women Who Are Receiving TREMFYA Therapeutically | 2027-08-31 |
Add all 3 to your calendar (.ics) → With an account.
Among the 29 studies testing guselkumab in Psoriasis, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Johnson & Johnson’s 76 in Psoriasis:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to demonstrate that Super-Responders (SRe; defined as psoriasis participants who receive on-label guselkumab treatment until week 20 and respond with a Psoriasis Area and Severity Index score (PASI) = 0 at weeks 20 and 28) maintain control of disease until week 68 with prolonged treatment intervals of 16 weeks (guselkumab 100 mg every 16 weeks).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants in group 1 (Part 1) will receive 100 milligram (mg) guselkumab subcutaneously (SC) at Weeks 0, 4, 12 and 20.
Drug: Guselkumab
Eligible participants from Part 1 will continue to participate in Part 2. Participants (super responder \[SRe\]) with a Psoriasis Area and Severity Index (PASI) score = 0 at weeks 20 and 28 will be randomized to guselkumab 100 mg every 8 weeks (q8w) (group 2a) or guselkumab 100 mg q16w (group 2b), at weeks 28 to 60. Group 2b will receive placebo injection at weeks 28, 44 and 60 to keep the comparison double blind. Participants losing control of disease (PASI score \>5) during study Part 2 (until week 60), will enter the re-treatment arm (group 2d) and receive guselkumab 100mg q8w (at re-treatment week 0), followed by administration at re-treatment-weeks 8 and 16.
Drug: Guselkumab
Participants (Non SRe) in group 2c with a PASI score greater than (\>) 0 at week 20 and/or 28 will continue to receive guselkumab 100 mg q8w until week 60.
Drug: Guselkumab · Drug: Placebo Injection
Participants from groups 2a and 2b with a PASI score \<3 at week 68 will be included in Part 3 (group 3a and 3b) and be withdrawn from guselkumab. Study visits will be conducted every 12 weeks until week 220 (follow-up). Participants with fluctuating disease (PASI score greater than or equal to \[\>=\] 3) at week 68 or PASI \>5 (participants losing control of disease) at any visit during part 3 after week 68 will get an opportunity to enter the re-treatment-arm (group 3c) in which participants will receive three guselkumab injections of 100 mg q8w.
Drug: Guselkumab
Participants will receive 100 mg guselkumab subcutaneously at Weeks 0, 4, 12 and 20 (group 1), at weeks 28, 36, 44, 52, 60 (group 2a and 2c), and at weeks 36 and 52 (group 2b). Group 2d and 3c are the re-treatment groups and will receive three injections after loss of disease control.
Also known as: TREMFYA
Participants of group 2b will receive matching placebo injection subcutaneously at weeks 28, 44 and 60.
Group 2a and Group 2b: Percentage of Participants Who Achieved an Absolute Psoriasis Area and Severity Index (PASI) Score Less Than (<) 3 at Week 68
Percentage of participants who achieved an absolute PASI \<3 at Week 68 were reported. The PASI is a system used for assessing and grading the severity of psoriatic lesions and their response to therapy. In the PASI system, the body is divided into 4 regions: the head, trunk, upper extremities, and lower extremities. Each of these areas is assessed separately for the percentage of the body surface area involved, which translates to a numeric score that ranged from 0 (indicated no involvement) to 6 (90 percent \[%\]-100% involvement), and for erythema, induration and scaling, which are each rated on a scale of 0 to 4. The PASI produces a numeric score that could range from 0 (no psoriasis) to 72 (maximum psoriasis). Higher score indicated greater severity of psoriasis.
Time frame: Week 68
Groups 1 and 2c: Time to Improvement From Baseline (Week 0) in PASI Score
Time to improvement from baseline in PASI 75/90/100 response for participants with short disease duration (SDD) and longer disease duration (LDD) was reported. PASI was used for assessing and grading severity of psoriatic lesions and their response to therapy. In PASI, body was divided into 4 regions: head, trunk, upper extremities, and lower extremities. Each of these areas was assessed separately for percentage of area involved, which translates to numeric score that ranged from 0 (no involvement) to 6 (90-100% involvement), and for erythema, induration, and scaling, which were each rated on a scale of 0 to 4. PASI produced numeric score ranging from 0 (no psoriasis) to 72 (maximum psoriasis). Higher score indicated more severe disease. PASI responders were participants with \>=75%, \>=90%, 100% improvement in PASI respectively. For Part 2, data is reported only for those groups in which participants had PASI improvement post Week 28.
Time frame: Group 1: Week 0 up to Week 28; Group 2c: Week 28 up to Week 68
Groups 1, 2a, 2b, 2c, 3a and 3b: Percentage of Participants With Short (<=2 Years) and Longer (>2 Years) Disease Duration Who Achieved an Absolute PASI Score of 0, <=1 and <3 at Weeks 20, 28, 68, 116, 164 and 220
Percentage of participants with short (\<=2 years) and longer (\>2 years) disease duration who achieved an absolute PASI Score of 0, \<=1 and less than (\<) 3 was reported. PASI was a system used for assessing and grading severity of psoriatic lesions and their response to therapy. In PASI, body was divided into 4 regions: head, trunk, upper extremities, and lower extremities. Each of these areas was assessed separately for percentage of area involved, which translated to numeric score that ranged from 0 (indicated no involvement) to 6 (90%-100% involvement), and for erythema, induration, and scaling, which were each rated on a scale of 0 to 4. PASI produced a numeric score that could range from 0 (no psoriasis) to 72 (maximum psoriasis). Higher score indicated more severe disease.
Time frame: Group 1: Weeks 20 and 28; Groups 2a, 2b, 2c: Week 68; Groups 3a and 3b: Weeks 116, 164 and 220
Group 3a and Group 3b: Percentage of Participants With Short (<=2 Years) and Longer (>2 Years) Disease Duration Who Retain Disease Control (Absolute PASI Score < 3)
Percentage of participants who retain disease control (that is, absolute PASI score \<3 from Week 68 through Week 220 for participants with short (\<= 2 years) and longer (\>2 years) disease duration was reported. Control of disease was defined as participants with a PASI score \<3. PASI was a system used for assessing and grading severity of psoriatic lesions and their response to therapy. In PASI, body was divided into 4 regions: head, trunk, upper extremities, and lower extremities. Each of these areas was assessed separately for percentage of area involved, which translated to numeric score that ranged from 0 (indicated no involvement) to 6 (90%-100% involvement), and for erythema, induration, and scaling, which were each rated on a scale of 0 to 4. PASI produced a numeric score that could range from 0 (no psoriasis) to 72 (maximum psoriasis). Higher score indicated more severe disease
Time frame: From Week 68 up to Week 220
Groups 1, 2a, 2b, 2c, 3a and 3b: Percentage of Participants Who Achieved a PASI 75/90/100 Response at Weeks 20, 28, 68, 116, 164, and 220
Percentage of participants who achieved PASI 75/90/100 response were reported. PASI was a system used for assessing and grading severity of psoriatic lesions and their response to therapy. In PASI, body was divided into 4 regions: head, trunk, upper extremities, and lower extremities. Each of these areas was assessed separately for percentage of area involved, which translated to numeric score that ranged from 0 (indicated no involvement) to 6 (90%-100% involvement), and for erythema, induration, and scaling, which were each rated on a scale of 0 to 4. PASI produced a numeric score that could range from 0 (no psoriasis) to 72 (maximum psoriasis). Higher score indicated more severe disease. PASI 75 responders were defined as participants with \>= 75% improvement in PASI from baseline. PASI 90 responders were defined as participants with \>= 90% improvement in PASI from baseline. PASI 100 responders were defined as participants with 100% improvement in PASI from baseline.
Time frame: Group 1: Weeks 20, 28; Groups 2a, 2b, 2c: Week 68; Groups 3a, 3b: Weeks 116, 164 and 220
Group 3a and Group 3b: Time to Loss of Disease Control (Absolute PASI Score >5) After Treatment Withdrawal
Time to loss of disease control (absolute PASI score \>5) after treatment withdrawal beyond Week 68 up to Week 220 were reported. PASI was a system used for assessing and grading severity of psoriatic lesions and their response to therapy. In PASI, body was divided into 4 regions: head, trunk, upper extremities, and lower extremities. Each of these areas was assessed separately for percentage of area involved, which translated to numeric score that ranged from 0 (indicated no involvement) to 6 (90%-100% involvement), and for erythema, induration, and scaling, which were each rated on a scale of 0 to 4. PASI produced a numeric score that could range from 0 (no psoriasis) to 72 (maximum psoriasis). Higher score indicated more severe disease.
Time frame: From Week 68 up to Week 220
Group 1: Percentage of Participants With an Absolute PASI Score = 0 at Weeks 12, 16, 20 and 28
Percentage of participants with an absolute PASI score = 0 at Weeks 12, 16, 20 and 28 were reported. PASI was a system used for assessing and grading severity of psoriatic lesions and their response to therapy. In PASI, body was divided into 4 regions: head, trunk, upper extremities, and lower extremities. Each of these areas was assessed separately for percentage of area involved, which translated to numeric score that ranged from 0 (indicated no involvement) to 6 (90%-100% involvement), and for erythema, induration, and scaling, which were each rated on a scale of 0 to 4. PASI produced a numeric score that could range from 0 (no psoriasis) to 72 (maximum psoriasis). Higher score indicated more severe disease.
Time frame: Weeks 12, 16, 20 and 28
Groups 1, 2a, 2b, 2c, 3a, 3b and 3c: Change From Baseline (Week 0) in Dermatology Life Quality Index (DLQI) Score
Change from baseline (Week 0) in DLQI score were reported. DLQI was a 10-item instrument questionnaire designed to assess the impact of the disease on a participant's quality of life. Each question was evaluated on a 4-point scale ranged from 0 (not at all) to 3 (very much); where higher scores indicated more impact on quality of life. Scores from all 10 questions added up to give DLQI total score ranged from 0 (not at all) to 30 (very much). Higher scores indicated more impact on quality of life of participants.
Time frame: Group 1: Baseline (Week 0), Week 28; Group 2a, 2b, 2c: Baseline (Week 0), Week 68; Group 3a and Group 3b:Baseline (Week 0), Week 116, 164 and 220; Group 3c: Baseline (Re-Treatment [R] Week 0), Week R24
Groups 1, 2a, 2b, 2c, 3a, 3b and 3c: Percentage of Participants Who Achieved a DLQI Score 0/1 and <5
Percentage of participants who achieved a DLQI score 0/1 and \<5 was reported. DLQI was a 10-item instrument questionnaire designed to assess the impact of the disease on a participant's quality of life. Each question was evaluated on a 4-point scale ranged from 0 (not at all) to 3 (very much); where higher scores indicated more impact on quality of life. Scores from all 10 questions added up to give DLQI total score ranged from 0 (not at all) to 30 (very much). Higher scores indicated more impact on quality of life of participants.
Time frame: Group 1: Week 28; Groups 2a, 2b, 2c: Week 68; Groups 3a and 3b: Week 116, 164 and 220; Group 3c: Week R24
Groups 1, 2a, 2b, 2c, 3a, and 3b: Percent Change From Baseline (Week 0) in Psoriasis- Affected Body Surface Area (BSA)
Percent change from baseline in the psoriasis affected BSA (%) was reported. The percentage of the psoriasis-affected BSA percentage is a system used for assessing the severity of psoriasis. The plaque coverage is estimated using the rule of palm (1 palm of the hand = 1% BSA)
Time frame: Group 1: Baseline (Week 0), Week 12, 28; Group 2a, 2b, 2c: Baseline (Week 0), Week 52 and 68, Group 3a, 3b: Baseline (Week 0), Week 80, 104, 116, 140, 164, 188, 212 and 220
Groups 1, 2a, 2b, 2c, 3a and 3b: Change From Baseline in Nail Assessment in Psoriasis and Psoriatic Arthritis- Clinical (NAPPA-CLIN) at Weeks 28, 68, 116, 164 and 220
Change from baseline in NAPPA-CLIN at Weeks 28, 68, 116 164, and 220 was reported. NAPPA-CLIN is an instrument used by the physician to assess the least and the worst involved nail of both hands or both feet with scores ranging from 0 (no involvement) to 16 (worst involvement). A higher score indicated a worst involvement.
Time frame: Group 1: Baseline (Week 0), Week 28; Group 2a, 2b, 2c: Baseline (Week 0), Week 68; Group 3a and Group 3b: Baseline (Week 0), Week 116, 164, and 220
Groups 1, 2a, 2b, 2c, 3a and 3b: Change From Baseline (Week 0) in the Signs and Symptoms Aggregate Scores of the Psoriasis Symptoms and Signs Diary (PSSD) at Weeks 28, 68, 116, 164 and 220
Change from baseline (Week 0) in the signs and symptoms aggregate scores of the PSSD at Weeks 28, 68, 116, 164 and 220 was reported. The PSSD was a questionnaire designed to measure the severity of psoriasis symptoms and signs for the assessment of treatment benefit. PSSD was a participant self-administered outcomes instrument that included 11 items covering symptoms (itch, pain, stinging, burning and skin tightness) and participant observable signs (skin dryness, cracking, scaling, shedding or flaking, redness and bleeding) using 0 to 10 numerical rating scales for severity. Two sub scores each ranging from 0 to 100 were derived: the psoriasis symptom score and the psoriasis sign score. A higher score indicated more severe disease. A change of \>= 40 points in PSSD symptom score or sign score, and a \>= 3-point change in individual PSSD item scale scores was defined as clinically meaningful change (response).
Time frame: Group 1: Baseline (Week 0), Week 28; Group 2a, 2b, 2c: Baseline (Week 0), Week 68; Group 3a and Group 3b: Baseline (Week 0), Week 116, 164, and 220
Groups 2a, 2b and 2c: Percentage of Participants Who Achieved a PSSD Sign Score = 0 at Week 68 in Participants With a PSSD Sign Score >= 1 at Week 28
Percentage of participants who achieved a PSSD sign score = 0 at Week 68 in participants with a PSSD sign score \>= 1 at Week 28 was reported. The PSSD was a questionnaire designed to measure the severity of psoriasis symptoms and signs for the assessment of treatment benefit. PSSD was a participant self-administered outcomes instrument that included 11 items covering symptoms (itch, pain, stinging, burning and skin tightness) and participant observable signs (skin dryness, cracking, scaling, shedding or flaking, redness and bleeding) using 0 to 10 numerical rating scales for severity. Two sub scores each ranging from 0 to 100 were derived: the psoriasis symptom score and the psoriasis sign score. A higher score indicated more severe disease.
Time frame: Week 68
Groups 2a and 2b: Serum Trough Guselkumab Levels at Weeks 20, 28, 36 and 68
Serum trough guselkumab levels at Weeks 20, 28, 36 were analyzed. Serum samples were analyzed to determine trough concentrations of guselkumab using a validated specific, and sensitive method. Week 28 data are presented in Part 2 arms (Groups 2a and 2b) as these groups were established at Week 28, however pre-Week 28 trough concentrations are also reported under these groups to assess potential differences between Part 1 PK characteristics.
Time frame: At Weeks 20, 28, 36, 68
Groups 2d and 3c: Percentage of Participants Who Were Re-Treated Due to Loss of Disease Control (PASI >5) and Regain Control of Disease (PASI <3) 24 Weeks After Start of Re-Treatment
Percentage of participants who were re-treated due to loss of disease control (PASI \>5) and regain control of disease (PASI \<3) 24 weeks after start of re-treatment was reported. PASI was a system used for assessing and grading severity of psoriatic lesions and their response to therapy. In PASI, body was divided into 4 regions: head, trunk, upper extremities, and lower extremities. Each of these areas was assessed separately for percentage of area involved, which translates to numeric score that ranged from 0 (indicates no involvement) to 6 (90%-100% involvement), and for erythema, induration, and scaling, which were each rated on a scale of 0 to 4. PASI produced a numeric score that could range from 0 (no psoriasis) to 72 (maximum psoriasis). Higher score indicated more severe disease.
Time frame: Week R0 up to Week R24
Groups 1, 2a, 2b, 2c, 2d,3a, 3b, and 3c: Percentage of Participants With Adverse Events as a Measure of Safety and Tolerability
An adverse event (AE) is any untoward medical occurrence in a clinical study participant administered a medicinal (investigational or non-investigational) product. An AE does not necessarily have a causal relationship with the treatment. An AE can therefore be any unfavorable and unintended sign (including an abnormal finding), symptom, or disease temporally associated with the use of a medicinal (investigational or non-investigational) product, whether or not related to that medicinal (investigational or non-investigational) product.
Time frame: Group 1: From Week 0 to Week 28; Group 2a,2b 2c: From Week 28 to Week 68; Group 3a, 3b: From Week 68 to Week 220; Group 2d, 3c: From Week R0 to Week R28
Groups 1, 2a, 2b, 2c, 2d, 3a,3b and 3c: Number of Participants With Clinically Significant Laboratory Abnormalities
Number of participants with clinically significant laboratory abnormalities was reported. Data of participants with at least one lab abnormality is reported. Abnormality criteria: Aspartate Aminotransferase (AST) \>3, Alanine Aminotransferase (ALT).\>5. For arm 3a and 3b, no drug was administered, hence no laboratory data was collected, per planned analysis.
Time frame: Group 1: Week 20, Group 2a, 2b,2c: Week 68 and Group 2d and 3c: Week R28
| Milestone | Part 1 Group 1: Guselkumab 100mg | Part 2 Group 2a: Guselkumab 100 mg Q8W | Part 2 Group 2b: Guselkumab 100 mg Q16W | Part 2 Group 2c: Guselkumab 100 mg Q8W | Part 2 Group 2d: Re-Treatment Guselkumab 100mg | Part 3 Group 3a: Withdrawal (Q8W) | Part 3 Group 3b: Withdrawal (Q16W) | Part 3 Group 3c: Re-Treatment Guselkumab 100mg |
|---|---|---|---|---|---|---|---|---|
| Started | 880 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Completed | 822 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Not completed | 58 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Lack of efficacy | 3 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Lost to follow-up | 10 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Protocol violation | 11 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Withdrawal by subject | 8 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Adverse event - worsening of psoriasis | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Adverse event - other | 16 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Non-compliance with study drug | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Other | 7 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Death | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Milestone | Part 1 Group 1: Guselkumab 100mg | Part 2 Group 2a: Guselkumab 100 mg Q8W | Part 2 Group 2b: Guselkumab 100 mg Q16W | Part 2 Group 2c: Guselkumab 100 mg Q8W | Part 2 Group 2d: Re-Treatment Guselkumab 100mg | Part 3 Group 3a: Withdrawal (Q8W) | Part 3 Group 3b: Withdrawal (Q16W) | Part 3 Group 3c: Re-Treatment Guselkumab 100mg |
|---|---|---|---|---|---|---|---|---|
| Started | 0 | 148 | 150 | 525 | 0 | 0 | 0 | 0 |
| Treated | 0 | 148 | 149 | 525 | 0 | 0 | 0 | 0 |
| Completed | 0 | 137 | 142 | 496 | 0 | 0 | 0 | 0 |
| Not completed | 0 | 11 | 8 | 29 | 0 | 0 | 0 | 0 |
| Withdrew: Lack of efficacy | 0 | 0 | 0 | 4 | 0 | 0 | 0 | 0 |
| Withdrew: Lost to follow-up | 0 | 6 | 1 | 9 | 0 | 0 | 0 | 0 |
| Withdrew: Withdrawal by subject | 0 | 0 | 0 | 8 | 0 | 0 | 0 | 0 |
| Withdrew: Other adverse events | 0 | 3 | 4 | 6 | 0 | 0 | 0 | 0 |
| Withdrew: Adverse event, serious fatal | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 |
| Withdrew: Participants started retreatment phase within study part 2 before week 68 | 0 | 1 | 2 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Other | 0 | 1 | 1 | 1 | 0 | 0 | 0 | 0 |
| Milestone | Part 1 Group 1: Guselkumab 100mg | Part 2 Group 2a: Guselkumab 100 mg Q8W | Part 2 Group 2b: Guselkumab 100 mg Q16W | Part 2 Group 2c: Guselkumab 100 mg Q8W | Part 2 Group 2d: Re-Treatment Guselkumab 100mg | Part 3 Group 3a: Withdrawal (Q8W) | Part 3 Group 3b: Withdrawal (Q16W) | Part 3 Group 3c: Re-Treatment Guselkumab 100mg |
|---|---|---|---|---|---|---|---|---|
| Started | 0 | 0 | 0 | 0 | 0 | 136 | 137 | 0 |
| Completed | 0 | 0 | 0 | 0 | 0 | 7 | 6 | 0 |
| Not completed | 0 | 0 | 0 | 0 | 0 | 129 | 131 | 0 |
| Withdrew: Lost to follow-up | 0 | 0 | 0 | 0 | 0 | 0 | 5 | 0 |
| Withdrew: Withdrawal by subject | 0 | 0 | 0 | 0 | 0 | 9 | 3 | 0 |
| Withdrew: Other adverse events | 0 | 0 | 0 | 0 | 0 | 0 | 2 | 0 |
| Withdrew: Non-compliance with study drug | 0 | 0 | 0 | 0 | 0 | 3 | 0 | 0 |
| Withdrew: Not signed icf | 0 | 0 | 0 | 0 | 0 | 5 | 4 | 0 |
| Withdrew: Other | 0 | 0 | 0 | 0 | 0 | 0 | 2 | 0 |
| Withdrew: Retreatment started | 0 | 0 | 0 | 0 | 0 | 112 | 115 | 0 |
| Milestone | Part 1 Group 1: Guselkumab 100mg | Part 2 Group 2a: Guselkumab 100 mg Q8W | Part 2 Group 2b: Guselkumab 100 mg Q16W | Part 2 Group 2c: Guselkumab 100 mg Q8W | Part 2 Group 2d: Re-Treatment Guselkumab 100mg | Part 3 Group 3a: Withdrawal (Q8W) | Part 3 Group 3b: Withdrawal (Q16W) | Part 3 Group 3c: Re-Treatment Guselkumab 100mg |
|---|---|---|---|---|---|---|---|---|
| Started | 0 | 0 | 0 | 0 | 9 | 0 | 0 | 227 |
| Completed | 0 | 0 | 0 | 0 | 9 | 0 | 0 | 219 |
| Not completed | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 8 |
| Withdrew: Lost to follow-up | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 3 |
| Withdrew: Withdrawal by subject | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 |
| Withdrew: Other adverse events | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 |
| Withdrew: Other | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 3 |
Percentage of participants who achieved an absolute PASI \<3 at Week 68 were reported. The PASI is a system used for assessing and grading the severity of psoriatic lesions and their response to therapy. In the PASI system, the body is divided into 4 regions: the head, trunk, upper extremities, and lower extremities. Each of these areas is assessed separately for the percentage of the body surface area involved, which translates to a numeric score that ranged from 0 (indicated no involvement) to 6 (90 percent \[%\]-100% involvement), and for erythema, induration and scaling, which are each rated on a scale of 0 to 4. The PASI produces a numeric score that could range from 0 (no psoriasis) to 72 (maximum psoriasis). Higher score indicated greater severity of psoriasis.
| Percentage of participants | Part 2 Group 2a: Guselkumab 100 mg Q8W | Part 2 Group 2b: Guselkumab 100 mg Q16W |
|---|---|---|
| Group 2a and Group 2b: Percentage of Participants Who Achieved an Absolute Psoriasis Area and Severity Index (PASI) Score Less Than (<) 3 at Week 68 | 92.6 (88.0 to 95.8) | 91.9 (87.3 to 95.3) |
Time to improvement from baseline in PASI 75/90/100 response for participants with short disease duration (SDD) and longer disease duration (LDD) was reported. PASI was used for assessing and grading severity of psoriatic lesions and their response to therapy. In PASI, body was divided into 4 regions: head, trunk, upper extremities, and lower extremities. Each of these areas was assessed separately for percentage of area involved, which translates to numeric score that ranged from 0 (no involvement) to 6 (90-100% involvement), and for erythema, induration, and scaling, which were each rated on a scale of 0 to 4. PASI produced numeric score ranging from 0 (no psoriasis) to 72 (maximum psoriasis). Higher score indicated more severe disease. PASI responders were participants with \>=75%, \>=90%, 100% improvement in PASI respectively. For Part 2, data is reported only for those groups in which participants had PASI improvement post Week 28.
| Days | Part 1 Group 1: Participants With Disease Duration <= 2 Years | Part 1 Group 1: Participants With Disease Duration > 2 Years | Part 2 Group 2c: Participants With Disease Duration <= 2 Years | Part 2 Group 2c: Participants With Duration > 2 Years |
|---|---|---|---|---|
| PASI 75 | 84.0 (81.0 to 89.0) | 84.0 (81.0 to 90.0) | 84.0 (83.0 to 112.0) | 84.0 (83.0 to 105.0) |
| PASI 90 | 89.0 (84.0 to 134.0) | 106.0 (84.0 to 140.0) | 112.0 (84.0 to 153.0) | 114.0 (84.0 to 196.0) |
| PASI 100 | 141.0 (105.0 to 210.0) | 200.0 (113.0 to NA) | 308.0 (196.0 to 483.0) | 416.0 (198 to NA) |
Percentage of participants with short (\<=2 years) and longer (\>2 years) disease duration who achieved an absolute PASI Score of 0, \<=1 and less than (\<) 3 was reported. PASI was a system used for assessing and grading severity of psoriatic lesions and their response to therapy. In PASI, body was divided into 4 regions: head, trunk, upper extremities, and lower extremities. Each of these areas was assessed separately for percentage of area involved, which translated to numeric score that ranged from 0 (indicated no involvement) to 6 (90%-100% involvement), and for erythema, induration, and scaling, which were each rated on a scale of 0 to 4. PASI produced a numeric score that could range from 0 (no psoriasis) to 72 (maximum psoriasis). Higher score indicated more severe disease.
| Percentage of participants | Part 1 Group 1: Participants With Disease Duration <= 2 Years | Part 1 Group 1: Participants With Disease Duration > 2 Years | Part 2 Group 2a: Participants With Disease Duration <= 2 Years | Part 2 Group 2a: Participants With Disease Duration > 2 Years | Part 2 Group 2b: Participants With Disease Duration <= 2 Years | Part 2 Group 2b: Participants With Disease Duration > 2 Years | Part 2 Group 2c: Participants With Disease Duration <= 2 Years | Part 2 Group 2c: Participants With Disease Duration > 2 Years | Part 3 Group 3a: Participants With Disease Duration <=2 Years | Part 3 Group 3a: Participants With Disease Duration> 2 Years | Part 3 Group 3b: Participants With Disease Duration <= 2 Years | Part 3 Group 3b: Participants With Disease Duration > 2 Years |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| PASI = 0 (Week 20) | 49.3 | 32.7 | — | — | — | — | — | — | — | — | — | — |
| PASI <=1 (Week 20) | 67.8 | 54.3 | — | — | — | — | — | — | — | — | — | — |
| PASI <3 (Week 20) | 85.2 | 82.4 | — | — | — | — | — | — | — | — | — | — |
| PASI = 0 ( Week 28) | 51.8 | 39.4 | — | — | — | — | — | — | — | — | — | — |
| PASI <=1 (Week 28) | 70.3 | 59.5 | — | — | — | — | — | — | — | — | — | — |
| PASI <3 (Week 28) | 86.8 | 83.9 | — | — | — | — | — | — | — | — | — | — |
| PASI = 0 (Week 68) | — | — | 81.3 | 80.8 | 73.7 | 64.4 | 39.9 | 37.2 | — | — | — | — |
| PASI <=1 (Week 68) | — | — | 86.7 | 93.2 | 81.6 | 76.7 | 73.6 | 55.9 | — | — | — | — |
| PASI <3 (Week 68) | — | — | 90.7 | 94.5 | 93.4 | 90.4 | 88.8 | 79.8 | — | — | — | — |
| PASI = 0 (Week 116) | — | — | — | — | — | — | — | — | 14.9 | 4.3 | 12.7 | 1.5 |
| PASI <=1 (Week 116) | — | — | — | — | — | — | — | — | 25.4 | 5.8 | 18.3 | 3.0 |
| PASI <3 (Week 116) | — | — | — | — | — | — | — | — | 34.3 | 11.6 | 26.8 | 10.6 |
| PASI = 0 (Week 164) | — | — | — | — | — | — | — | — | 10.4 | 1.4 | 5.6 | 0.0 |
| PASI <=1 (Week 164) | — | — | — | — | — | — | — | — | 13.4 | 1.4 | 7.0 | 0.0 |
| PASI <3 (Week 164) | — | — | — | — | — | — | — | — | 14.9 | 2.9 | 12.7 | 3.0 |
| PASI = 0 (Week 220) | — | — | — | — | — | — | — | — | 9.0 | 0 | 5.6 | 0 |
| PASI <=1 (Week 220) | — | — | — | — | — | — | — | — | 9.0 | 0 | 5.6 | 0 |
| PASI <3 (Week 220) | — | — | — | — | — | — | — | — | 10.4 | 0 | 7.0 | 1.5 |
Percentage of participants who retain disease control (that is, absolute PASI score \<3 from Week 68 through Week 220 for participants with short (\<= 2 years) and longer (\>2 years) disease duration was reported. Control of disease was defined as participants with a PASI score \<3. PASI was a system used for assessing and grading severity of psoriatic lesions and their response to therapy. In PASI, body was divided into 4 regions: head, trunk, upper extremities, and lower extremities. Each of these areas was assessed separately for percentage of area involved, which translated to numeric score that ranged from 0 (indicated no involvement) to 6 (90%-100% involvement), and for erythema, induration, and scaling, which were each rated on a scale of 0 to 4. PASI produced a numeric score that could range from 0 (no psoriasis) to 72 (maximum psoriasis). Higher score indicated more severe disease
| Percentage of participants | Part 3 Group 3a: Participants With Disease Duration <=2 Years | Part 3 Group 3a: Participants With Disease Duration> 2 Years | Part 3 Group 3b: Participants With Disease Duration <= 2 Years | Part 3 Group 3b: Participants With Disease Duration > 2 Years |
|---|---|---|---|---|
| Group 3a and Group 3b: Percentage of Participants With Short (<=2 Years) and Longer (>2 Years) Disease Duration Who Retain Disease Control (Absolute PASI Score < 3) | 7.5 (2.5 to 16.6) | 0.0 (0.0 to 5.2) | 2.8 (0.3 to 9.8) | 1.5 (0.0 to 8.2) |
Percentage of participants who achieved PASI 75/90/100 response were reported. PASI was a system used for assessing and grading severity of psoriatic lesions and their response to therapy. In PASI, body was divided into 4 regions: head, trunk, upper extremities, and lower extremities. Each of these areas was assessed separately for percentage of area involved, which translated to numeric score that ranged from 0 (indicated no involvement) to 6 (90%-100% involvement), and for erythema, induration, and scaling, which were each rated on a scale of 0 to 4. PASI produced a numeric score that could range from 0 (no psoriasis) to 72 (maximum psoriasis). Higher score indicated more severe disease. PASI 75 responders were defined as participants with \>= 75% improvement in PASI from baseline. PASI 90 responders were defined as participants with \>= 90% improvement in PASI from baseline. PASI 100 responders were defined as participants with 100% improvement in PASI from baseline.
| Percentage of participants | Part 1 Group 1: Guselkumab 100mg | Part 2 Group 2a: Guselkumab 100 mg Q8W | Part 2 Group 2b: Guselkumab 100 mg Q16W | Part 2 Group 2c: Guselkumab 100 mg Q8W | Part 3 Group 3a: Withdrawal (Q8W) | Part 3 Group 3b: Withdrawal (Q16W) |
|---|---|---|---|---|---|---|
| PASI 75 (Week 20) | 90.2 | — | — | — | — | — |
| PASI 75 (Week 28) | 90.7 | — | — | — | — | — |
| PASI 90 (Week 20) | 73.6 | — | — | — | — | — |
| PASI 90 (Week 28) | 76.0 | — | — | — | — | — |
| PASI 100 (Week 20) | 39.4 | — | — | — | — | — |
| PASI 100 (Week 28) | 44.4 | — | — | — | — | — |
| PASI 75 (Week 68) | — | 92.6 | 94.0 | 88.0 | — | — |
| PASI 90 (Week 68) | — | 91.9 | 85.9 | 73.7 | — | — |
| PASI 100 (Week 68) | — | 81.1 | 69.1 | 38.1 | — | — |
| PASI 75 (Week 116) | — | — | — | — | 27.9 | 20.4 |
| PASI 75 (Week 164) | — | — | — | — | 10.3 | 8.0 |
| PASI 75 (Week 220) | — | — | — | — | 5.1 | 4.4 |
| PASI 90 (Week 116) | — | — | — | — | 18.4 | 13.1 |
| PASI 90 (Week 164) | — | — | — | — | 7.4 | 5.8 |
| PASI 90 (Week 220) | — | — | — | — | 5.1 | 2.9 |
| PASI 100 (Week 116) | — | — | — | — | 9.6 | 7.3 |
| PASI 100 (Week 164) | — | — | — | — | 5.9 | 2.9 |
| PASI 100 (Week 220) | — | — | — | — | 4.4 | 2.9 |
Time to loss of disease control (absolute PASI score \>5) after treatment withdrawal beyond Week 68 up to Week 220 were reported. PASI was a system used for assessing and grading severity of psoriatic lesions and their response to therapy. In PASI, body was divided into 4 regions: head, trunk, upper extremities, and lower extremities. Each of these areas was assessed separately for percentage of area involved, which translated to numeric score that ranged from 0 (indicated no involvement) to 6 (90%-100% involvement), and for erythema, induration, and scaling, which were each rated on a scale of 0 to 4. PASI produced a numeric score that could range from 0 (no psoriasis) to 72 (maximum psoriasis). Higher score indicated more severe disease.
| Days | Part 3 Group 3a: Withdrawal (Q8W) | Part 3 Group 3b: Withdrawal (Q16W) |
|---|---|---|
| Group 3a and Group 3b: Time to Loss of Disease Control (Absolute PASI Score >5) After Treatment Withdrawal | 245 (203 to 286) | 189 (166 to 251) |
Percentage of participants with an absolute PASI score = 0 at Weeks 12, 16, 20 and 28 were reported. PASI was a system used for assessing and grading severity of psoriatic lesions and their response to therapy. In PASI, body was divided into 4 regions: head, trunk, upper extremities, and lower extremities. Each of these areas was assessed separately for percentage of area involved, which translated to numeric score that ranged from 0 (indicated no involvement) to 6 (90%-100% involvement), and for erythema, induration, and scaling, which were each rated on a scale of 0 to 4. PASI produced a numeric score that could range from 0 (no psoriasis) to 72 (maximum psoriasis). Higher score indicated more severe disease.
| Percentage of participants | Part 1 Group 1: Guselkumab 100 mg |
|---|---|
| Week 12 | 17.8 |
| Week 16 | 29.0 |
| Week 20 | 39.4 |
| Week 28 | 44.4 |
Change from baseline (Week 0) in DLQI score were reported. DLQI was a 10-item instrument questionnaire designed to assess the impact of the disease on a participant's quality of life. Each question was evaluated on a 4-point scale ranged from 0 (not at all) to 3 (very much); where higher scores indicated more impact on quality of life. Scores from all 10 questions added up to give DLQI total score ranged from 0 (not at all) to 30 (very much). Higher scores indicated more impact on quality of life of participants.
| Score on scale | Part 1 Group 1: Guselkumab 100mg | Part 2 Group 2a: Guselkumab 100 mg Q8W | Part 2 Group 2b: Guselkumab 100 mg Q16W | Part 2 Group 2c: Guselkumab 100 mg Q8W | Part 3 Group 3a: Withdrawal (Q8W) | Part 3 Group 3b: Withdrawal (Q16W) | Part 3 Group 3c: Re-Treatment Guselkumab 100mg |
|---|---|---|---|---|---|---|---|
| Week 28 | -16.6 ± 6.2 | — | — | — | — | — | — |
| Week 68 | — | -18.8 ± 5.6 | -17.0 ± 5.5 | -17.1 ± 5.8 | — | — | — |
| Week 116 | — | — | — | — | -16.5 ± 6.3 | -15.5 ± 6.4 | — |
| Week 164 | — | — | — | — | -18.1 ± 6.7 | -17.4 ± 7.8 | — |
| Week 220 | — | — | — | — | -20.9 ± 6.0 | -16.3 ± 6.5 | — |
| Re-Treatment till R24 weeks | — | — | — | — | — | — | -10.1 ± 6.8 |
Percentage of participants who achieved a DLQI score 0/1 and \<5 was reported. DLQI was a 10-item instrument questionnaire designed to assess the impact of the disease on a participant's quality of life. Each question was evaluated on a 4-point scale ranged from 0 (not at all) to 3 (very much); where higher scores indicated more impact on quality of life. Scores from all 10 questions added up to give DLQI total score ranged from 0 (not at all) to 30 (very much). Higher scores indicated more impact on quality of life of participants.
| Percentage of participants | Part 1 Group 1: Guselkumab 100mg | Part 2 Group 2a: Guselkumab 100 mg Q8W | Part 2 Group 2b: Guselkumab 100 mg Q16W | Part 2 Group 2c: Guselkumab 100 mg Q8W | Part 3 Group 3a: Withdrawal (Q8W) | Part 3 Group 3b: Withdrawal (Q16W) | Part 3 Group 3a: Participants With Disease Duration <=2 Years | Part 3 Group 3a: Participants With Disease Duration> 2 Years | Part 3 Group 3b: Participants With Disease Duration <= 2 Years | Part 3 Group 3b: Participants With Disease Duration > 2 Years | Part 3 Group 3c: Re-Treatment Guselkumab 100mg |
|---|---|---|---|---|---|---|---|---|---|---|---|
| DLQI Score 0/1 (Week 28) | 60.9 | — | — | — | — | — | — | — | — | — | — |
| DLQI Score<5 (Week 28) | 78.4 | — | — | — | — | — | — | — | — | — | — |
| DLQI Score 0/1 (Week 68) | — | 83.1 | 77.9 | 61.9 | — | — | — | — | — | — | — |
| DLQI Score<5 (Week 68) | — | 89.2 | 85.2 | 78.9 | — | — | — | — | — | — | — |
| DLQI Score 0/1 (Week 116) | — | — | — | — | 15.4 | 10.9 | — | — | — | — | — |
| DLQI Score <5 (Week 116) | — | — | — | — | — | — | 34.3 | 15.9 | 26.8 | 7.6 | — |
| DLQI Score 0/1 (Week 164) | — | — | — | — | 8.1 | 5.8 | — | — | — | — | — |
| DLQI Score <5 (Week 164) | — | — | — | — | 8.1 | 8.0 | — | — | — | — | — |
| DLQI Score 0/1 (Week 220) | — | — | — | — | 4.4 | 2.9 | — | — | — | — | — |
| DLQI Score <5 (Week 220) | — | — | — | — | 5.1 | 4.4 | — | — | — | — | — |
| DLQI Score 0/1 RT24 | — | — | — | — | — | — | — | — | — | — | 73.1 |
| DLQI Score <5 RT24 | — | — | — | — | — | — | — | — | — | — | 87.7 |
Percent change from baseline in the psoriasis affected BSA (%) was reported. The percentage of the psoriasis-affected BSA percentage is a system used for assessing the severity of psoriasis. The plaque coverage is estimated using the rule of palm (1 palm of the hand = 1% BSA)
| Percent Change | Part 1 Group 1: Guselkumab 100mg | Part 2 Group 2a: Guselkumab 100 mg Q8W | Part 2 Group 2b: Guselkumab 100 mg Q16W | Part 2 Group 2c: Guselkumab 100 mg Q8W | Part 3 Group 3a: Withdrawal (Q8W) | Part 3 Group 3b: Withdrawal (Q16W) |
|---|---|---|---|---|---|---|
| At Week 12 | -19.3 ± 14.2 | — | — | — | — | — |
| At Week 28 | -23.8 ± 15.0 | — | — | — | — | — |
| At Week 52 | — | -25.1 ± 15.1 | -24.3 ± 15.6 | -24.8 ± 14.6 | — | — |
| At Week 68 | — | -24.8 ± 14.9 | -24.3 ± 15.8 | -25.0 ± 14.6 | — | — |
| At Week 80 | — | — | — | — | -23.8 ± 14.1 | -23.6 ± 15.6 |
| At Week 104 | — | — | — | — | -20.6 ± 15.1 | -22.5 ± 16.8 |
| At Week 116 | — | — | — | — | -22.4 ± 16.8 | -19.8 ± 13.0 |
| At Week 140 | — | — | — | — | -16.7 ± 8.5 | -19.6 ± 11.2 |
| At Week 164 | — | — | — | — | -18.2 ± 8.7 | -20.6 ± 11.2 |
| At Week 188 | — | — | — | — | -18.1 ± 8.2 | -20.4 ± 13.0 |
| At Week 212 | — | — | — | — | -18.3 ± 9.6 | -19.3 ± 13.9 |
| At Week 220 | — | — | — | — | -18.3 ± 9.6 | 19.0 ± 13.6 |
Change from baseline in NAPPA-CLIN at Weeks 28, 68, 116 164, and 220 was reported. NAPPA-CLIN is an instrument used by the physician to assess the least and the worst involved nail of both hands or both feet with scores ranging from 0 (no involvement) to 16 (worst involvement). A higher score indicated a worst involvement.
| Score on scale | Part 1 Group 1: Guselkumab 100mg | Part 2 Group 2a: Guselkumab 100 mg Q8W | Part 2 Group 2b: Guselkumab 100 mg Q16W | Part 2 Group 2c: Guselkumab 100 mg Q8W | Part 3 Group 3a: Withdrawal (Q8W) | Part 3 Group 3b: Withdrawal (Q16W) |
|---|---|---|---|---|---|---|
| Hands (Week 28) | -3.4 ± 3.2 | — | — | — | — | — |
| Feet (Week 28) | -3.1 ± 3.5 | — | — | — | — | — |
| Hands (Week 68) | — | -4.0 ± 3.2 | -4.5 ± 3.5 | -4.0 ± 3.2 | — | — |
| Feet (Week 68) | — | -4.9 ± 3.5 | -4.6 ± 3.7 | -4.1 ± 3.6 | — | — |
| Hands (Week 116) | — | — | — | — | -2.2 ± 4.3 | -2.2 ± 3.2 |
| Feet (Week 116) | — | — | — | — | -3.4 ± 6.2 | -3.5 ± 3.9 |
| Hands (Week 164) | — | — | — | — | -4.5 ± 3.5 | -3.0 ± 2.4 |
| Feet (Week 164) | — | — | — | — | -8.0 ± NA | -3.6 ± 3.1 |
| Hands (Week 220) | — | — | — | — | -4.3 ± 2.5 | -3.7 ± 2.5 |
| Feet (Week 220) | — | — | — | — | -8.0 ± NA | -4.0 ± 3.5 |
Change from baseline (Week 0) in the signs and symptoms aggregate scores of the PSSD at Weeks 28, 68, 116, 164 and 220 was reported. The PSSD was a questionnaire designed to measure the severity of psoriasis symptoms and signs for the assessment of treatment benefit. PSSD was a participant self-administered outcomes instrument that included 11 items covering symptoms (itch, pain, stinging, burning and skin tightness) and participant observable signs (skin dryness, cracking, scaling, shedding or flaking, redness and bleeding) using 0 to 10 numerical rating scales for severity. Two sub scores each ranging from 0 to 100 were derived: the psoriasis symptom score and the psoriasis sign score. A higher score indicated more severe disease. A change of \>= 40 points in PSSD symptom score or sign score, and a \>= 3-point change in individual PSSD item scale scores was defined as clinically meaningful change (response).
| Score on scale | Part 1 Group 1: Guselkumab 100mg | Part 2 Group 2a: Guselkumab 100 mg Q8W | Part 2 Group 2b: Guselkumab 100 mg Q16W | Part 2 Group 2c: Guselkumab 100 mg Q8W | Part 3 Group 3a: Withdrawal (Q8W) | Part 3 Group 3b: Withdrawal (Q16W) |
|---|---|---|---|---|---|---|
| At Week 28 (Symptom) | -57.2 ± 25.4 | — | — | — | — | — |
| At Week 28 (Sign) | -62.1 ± 22.0 | — | — | — | — | — |
| At Week 68 (Symptom) | — | -65.1 ± 21.2 | -58.7 ± 23.3 | -58.6 ± 25.1 | — | — |
| At Week 68 (Sign) | — | -71.7 ± 16.4 | -65.4 ± 19.6 | -63.0 ± 22.2 | — | — |
| At Week 116 (Symptom) | — | — | — | — | -52.3 ± 25.7 | -50.0 ± 24.3 |
| At Week 116 (Sign) | — | — | — | — | -56.1 ± 25.6 | -52.2 ± 24.3 |
| At Week 164 (Symptom) | — | — | — | — | -59.7 ± 20.5 | -54.0 ± 26.1 |
| At Week 164 (Sign) | — | — | — | — | -62.1 ± 22.0 | -50.4 ± 26.5 |
| At Week 220 (Symptom) | — | — | — | — | -56.0 ± 22.9 | -54.7 ± 23.1 |
| At Week 220 (Sign) | — | — | — | — | -63.3 ± 20.3 | -54.7 ± 28.5 |
Percentage of participants who achieved a PSSD sign score = 0 at Week 68 in participants with a PSSD sign score \>= 1 at Week 28 was reported. The PSSD was a questionnaire designed to measure the severity of psoriasis symptoms and signs for the assessment of treatment benefit. PSSD was a participant self-administered outcomes instrument that included 11 items covering symptoms (itch, pain, stinging, burning and skin tightness) and participant observable signs (skin dryness, cracking, scaling, shedding or flaking, redness and bleeding) using 0 to 10 numerical rating scales for severity. Two sub scores each ranging from 0 to 100 were derived: the psoriasis symptom score and the psoriasis sign score. A higher score indicated more severe disease.
| Percentage of participants | Part 2 Group 2a: Guselkumab 100 mg Q8W | Part 2 Group 2b: Guselkumab 100 mg Q16W | Part 2 Group 2c: Guselkumab 100 mg Q8W |
|---|---|---|---|
| Groups 2a, 2b and 2c: Percentage of Participants Who Achieved a PSSD Sign Score = 0 at Week 68 in Participants With a PSSD Sign Score >= 1 at Week 28 | 30.2 (22.1 to 39.4) | 21.7 (14.9 to 30.0) | 14.8 (12.1 to 17.8) |
Serum trough guselkumab levels at Weeks 20, 28, 36 were analyzed. Serum samples were analyzed to determine trough concentrations of guselkumab using a validated specific, and sensitive method. Week 28 data are presented in Part 2 arms (Groups 2a and 2b) as these groups were established at Week 28, however pre-Week 28 trough concentrations are also reported under these groups to assess potential differences between Part 1 PK characteristics.
| micrograms/mL | Part 2 Group 2a: Guselkumab 100 mg Q8W | Part 2 Group 2b: Guselkumab 100 mg Q16W |
|---|---|---|
| At Week 20 | 1.61 ± 0.989 | 1.60 ± 1.049 |
| At Week 28 | 1.58 ± 1.010 | 1.67 ± 1.076 |
| At Week 36 | 1.68 ± 1.062 | 0.38 ± 0.396 |
| At Week 68 | 1.56 ± 0.960 | 0.31 ± 0.377 |
Percentage of participants who were re-treated due to loss of disease control (PASI \>5) and regain control of disease (PASI \<3) 24 weeks after start of re-treatment was reported. PASI was a system used for assessing and grading severity of psoriatic lesions and their response to therapy. In PASI, body was divided into 4 regions: head, trunk, upper extremities, and lower extremities. Each of these areas was assessed separately for percentage of area involved, which translates to numeric score that ranged from 0 (indicates no involvement) to 6 (90%-100% involvement), and for erythema, induration, and scaling, which were each rated on a scale of 0 to 4. PASI produced a numeric score that could range from 0 (no psoriasis) to 72 (maximum psoriasis). Higher score indicated more severe disease.
| Percentage of participants | Part 2 Group 2d: Re-Treatment Guselkumab 100mg | Part 3 Group 3c: Re-Treatment Guselkumab 100mg |
|---|---|---|
| Groups 2d and 3c: Percentage of Participants Who Were Re-Treated Due to Loss of Disease Control (PASI >5) and Regain Control of Disease (PASI <3) 24 Weeks After Start of Re-Treatment | 88.8 (29.2 to 100.0) | 98.2 (95.5 to 99.5) |
An adverse event (AE) is any untoward medical occurrence in a clinical study participant administered a medicinal (investigational or non-investigational) product. An AE does not necessarily have a causal relationship with the treatment. An AE can therefore be any unfavorable and unintended sign (including an abnormal finding), symptom, or disease temporally associated with the use of a medicinal (investigational or non-investigational) product, whether or not related to that medicinal (investigational or non-investigational) product.
| Percentage of participants | Part 1 Group 1: Guselkumab 100mg | Part 2 Group 2a: Guselkumab 100 mg Q8W | Part 2 Group 2b: Guselkumab 100 mg Q16W | Part 2 Group 2c: Guselkumab 100 mg Q8W | Part 2 Group 2d: Re-Treatment Guselkumab 100mg | Part 3 Group 3a: Withdrawal (Q8W) | Part 3 Group 3b: Withdrawal (Q16W) | Part 3 Group 3c: Re-Treatment Guselkumab 100mg |
|---|---|---|---|---|---|---|---|---|
| From Week 0 to Week 28 | 74.8 | — | — | — | — | — | — | — |
| From Week 28 to Week 68 | — | 68.9 | 69.8 | 72.0 | — | — | — | — |
| Week 68 to Week 220 | — | — | — | — | — | 55.1 | 55.5 | — |
| From Week R0 to Week R28 | — | — | — | — | 66.6 | — | — | 58.1 |
Number of participants with clinically significant laboratory abnormalities was reported. Data of participants with at least one lab abnormality is reported. Abnormality criteria: Aspartate Aminotransferase (AST) \>3, Alanine Aminotransferase (ALT).\>5. For arm 3a and 3b, no drug was administered, hence no laboratory data was collected, per planned analysis.
| Participants | Part 1 Group 1: Guselkumab 100mg | Part 2 Group 2a: Guselkumab 100 mg Q8W | Part 2 Group 2b: Guselkumab 100 mg Q16W | Part 2 Group 2c: Guselkumab 100 mg Q8W | Part 2 Group 2d: Re-Treatment Guselkumab 100mg | Part 3 Group 3c: Re-Treatment Guselkumab 100mg |
|---|---|---|---|---|---|---|
| AST > 3 (Week 20) | 2 | — | — | — | — | — |
| AST > 3 (Week 68) | — | 1 | 0 | 1 | 0 | — |
| ALT > 5 (Week 68) | — | 1 | 1 | 0 | 0 | — |
| AST > 3 (Week R28) | — | — | — | — | — | 0 |
| ALT > 5 (Week R28) | — | — | — | — | — | 1 |
Collected over Group 1: All-cause mortality: From screening (Week -4) to Week 28; serious and other AEs: Week0 to Week 28; Groups 2a,2b,2c (all-cause mortality and SAEs/other AEs): Week 28 to Week 68; Groups 3a, 3b (all-cause mortality and SAEs/other AEs): Week 68 to Week 220; Groups 2d, 3c (all-cause mortality and SAEs/other AEs): Week R0 to Week R28. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Part 1 Group 1: Guselkumab 100mg | 1/880 (0.1%) | 38/880 (4.3%) | 631/880 (71.7%) |
| Group 2a: Guselkumab 100 mg Q8W | 0/148 (0%) | 7/148 (4.7%) | 101/148 (68.2%) |
| Group 2b: Guselkumab 100 mg Q16W | 0/150 (0%) | 6/149 (4%) | 103/149 (69.1%) |
| Group 2c: Guselkumab 100 mg Q8W | 1/525 (0.2%) | 33/525 (6.3%) | 367/525 (69.9%) |
| Part 2 Group 2d: Re-Treatment Guselkumab 100mg | 0/9 (0%) | 0/9 (0%) | 6/9 (66.7%) |
| Group 3a Guselkumab 100 mg Q8W | 0/136 (0%) | 3/136 (2.2%) | 75/136 (55.1%) |
| Group 3b Guselkumab 100 mg Q16W | 0/137 (0%) | 9/137 (6.6%) | 75/137 (54.7%) |
| Group 3c Guselkumab 100 mg | 0/227 (0%) | 8/227 (3.5%) | 130/227 (57.3%) |
| Event | Part 1 Group 1: Guselkumab 100mg | Group 2a: Guselkumab 100 mg Q8W | Group 2b: Guselkumab 100 mg Q16W | Group 2c: Guselkumab 100 mg Q8W | Part 2 Group 2d: Re-Treatment Guselkumab 100mg | Group 3a Guselkumab 100 mg Q8W | Group 3b Guselkumab 100 mg Q16W | Group 3c Guselkumab 100 mg |
|---|---|---|---|---|---|---|---|---|
| Ligament RuptureInjury, poisoning and procedural complications | 0/880 | 0/148 | 0/149 | 1/525 | 0/9 | 0/136 | 2/137 | 0/227 |
| DepressionPsychiatric disorders | 1/880 | 0/148 | 0/149 | 0/525 | 0/9 | 0/136 | 0/137 | 2/227 |
| Hiatus HerniaGastrointestinal disorders | 0/880 | 0/148 | 0/149 | 0/525 | 0/9 | 1/136 | 0/137 | 0/227 |
| Ankle FractureInjury, poisoning and procedural complications | 1/880 | 0/148 | 0/149 | 0/525 | 0/9 | 1/136 | 0/137 | 1/227 |
| SeromaInjury, poisoning and procedural complications | 0/880 | 0/148 | 0/149 | 0/525 | 0/9 | 1/136 | 0/137 | 0/227 |
| PancreatitisGastrointestinal disorders | 0/880 | 0/148 | 0/149 | 0/525 | 0/9 | 0/136 | 1/137 | 0/227 |
| Foot FractureInjury, poisoning and procedural complications | 1/880 | 0/148 | 0/149 | 0/525 | 0/9 | 0/136 | 1/137 | 0/227 |
| Back PainMusculoskeletal and connective tissue disorders | 0/880 | 0/148 | 0/149 | 0/525 | 0/9 | 0/136 | 1/137 | 0/227 |
| BursitisMusculoskeletal and connective tissue disorders | 1/880 | 0/148 | 0/149 | 0/525 | 0/9 | 0/136 | 1/137 | 0/227 |
| CraniopharyngiomaNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/880 | 0/148 | 0/149 | 0/525 | 0/9 | 0/136 | 1/137 | 0/227 |
| Event | Part 1 Group 1: Guselkumab 100mg | Group 2a: Guselkumab 100 mg Q8W | Group 2b: Guselkumab 100 mg Q16W | Group 2c: Guselkumab 100 mg Q8W | Part 2 Group 2d: Re-Treatment Guselkumab 100mg | Group 3a Guselkumab 100 mg Q8W | Group 3b Guselkumab 100 mg Q16W | Group 3c Guselkumab 100 mg |
|---|---|---|---|---|---|---|---|---|
| NasopharyngitisInfections and infestations | 214/880 | 26/148 | 23/149 | 97/525 | 0/9 | 17/136 | 17/137 | 32/227 |
| Nail psoriasisNervous system disorders | 0/880 | 0/148 | 0/149 | 0/525 | 2/9 | 0/136 | 0/137 | 0/227 |
| Covid-19Infections and infestations | 10/880 | 4/148 | 3/149 | 13/525 | 1/9 | 20/136 | 12/137 | 21/227 |
| Erythema MigransInfections and infestations | 0/880 | 1/148 | 0/149 | 0/525 | 1/9 | 0/136 | 0/137 | 0/227 |
| Genital Infection FungalInfections and infestations | 1/880 | 0/148 | 0/149 | 1/525 | 1/9 | 0/136 | 0/137 | 0/227 |
| Otitis MediaInfections and infestations | 1/880 | 1/148 | 0/149 | 3/525 | 1/9 | 0/136 | 0/137 | 0/227 |
| Urinary Tract InfectionInfections and infestations | 8/880 | 1/148 | 3/149 | 4/525 | 1/9 | 1/136 | 1/137 | 1/227 |
| Back PainMusculoskeletal and connective tissue disorders | 26/880 | 6/148 | 8/149 | 13/525 | 1/9 | 4/136 | 2/137 | 3/227 |
| HeadacheNervous system disorders | 0/880 | 0/148 | 0/149 | 0/525 | 1/9 | 0/136 | 0/137 | 0/227 |
| Pruritus genitalReproductive system and breast disorders | 0/880 | 0/148 | 0/149 | 0/525 | 1/9 | 0/136 | 0/137 | 0/227 |
| Age, Categorical(Participants) | Part 1 Group 1: Guselkumab 100 mg |
|---|---|
| <=18 years | 0 |
| Between 18 and 65 years | 817 |
| >=65 years | 63 |
| Age, Continuous(years) | Part 1 Group 1: Guselkumab 100 mg |
|---|---|
| Mean | 42.5 ± 14.7 |
| Sex: Female, Male(Participants) | Part 1 Group 1: Guselkumab 100 mg |
|---|---|
| Female | 260 |
| Male | 620 |
| Race/Ethnicity, Customized(Participants) | Part 1 Group 1: Guselkumab 100 mg |
|---|---|
| Asian | 8 |
| Black | 1 |
| White | 859 |
| More than one race | 2 |
| Unknown or Not Reported | 3 |
| Other | 7 |
| Region of Enrollment(Participants) | Part 1 Group 1: Guselkumab 100 mg |
|---|---|
| FRANCE | 52 |
| GERMANY | 828 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — The data sharing policy of the Janssen Pharmaceutical Companies of Johnson \& Johnson is available at www.janssen.com/clinical-trials/transparency. As noted on this site, requests for access to the study data can be submitted through Yale Open Data Access (YODA) Project site at yoda.yale.edu
Data sharing details ↗ · www.janssen.com
Ran from Feb 2019 to primary completion in Mar 2022, 36 months.
Results were first posted in May 2023, 1 year 2 months after primary completion.
Of 217 industry-sponsored phase 3 interventional studies under Psoriasis, half reached primary completion within 15 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 26. This study's 36 months is above that.
Counting every sponsor, half of 227 studies reached it within 15 months; a quarter within 10 and three quarters within 26.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jan 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Guselkumab
Janssen-Cilag International NV →